Liquid Biopsy Global Market - Forecast to 2024
According to IQ4I analysis, the liquid biopsy global market is projected to grow at double digit CAGR to reach $8,730.4 million by 2024.
The liquid biopsy market by Biomarkers is segmented into circulating tumor cells (CTC), cell-free DNA and Exosomes & Others, among which, the Cell-free DNA market commanded the largest share of the market & growing at double digit CAGR from 2017-2024. The utilization of circulating tumor cell as an invaluable research tool is expected to propel this market at a strong CAGR from 2017 to 2024.
The applications market is segmented into oncology testing, prenatal (NIPT) testing and transplantation diagnostics where oncology testing dominates the application with market which is followed by prenatal testing (NIPT) in 2017, however, the rapid adoption of cfDNA based transplantation diagnostics testing is expected to drive this market at strong CAGR during forecasting period.
The oncology testing market is segmented based on type of cancer into breast cancer, colorectal cancer, lung cancer, prostate cancer, melanoma, ovarian cancer and others, where, breast cancer commanded largest share in 2017, lung cancer is projected to grow at highest CAGR from 2017 to 2024. The oncology testing market is segmented based on cancer care into early screening, companion diagnostics, prognosis and recurrence monitoring. The companion diagnostics monitoring market dominates with share in 2017, while early screening is expected to grow at strong CAGR of 22.3% from 2017 to 2024.
The liquid biopsy sample market includes into blood, urine and others where blood dominates the market revenue of $1,881.9 million in 2017 and is expected to maintain the position with strong CAGR growth during forecasting period.
The end-users market is segmented into Hospitals and academic and research institutes. Hospitals attracted the largest revenue in 2017 and are expected to show strong CAGR from 2017 to 2024.
The liquid biopsy geographical market consists of North America, Europe, Asia-Pacific and RoW where North America dominates the market in 2017 followed by Europe. Asia-Pacific market is expected to show highest growth rate during forecasting period.
The report provides an in depth market analysis of the above mentioned segments across the following regions:
- North America
- Europe
- Asia-Pacific
- Rest of the World (RoW)
2 INTRODUCTION
2.1 KEY TAKE AWAYS
2.2 REPORT DESCRIPTION
2.3 MARKETS COVERED
2.4 STAKEHOLDERS
2.5 RESEARCH METHODOLOGY
2.5.1 MARKET SIZE ESTIMATION
2.5.2 MARKET CRACKDOWN AND DATATRIANGULATION
2.5.3 SECONDARY SOURCES
2.5.4 KEY DATA POINTS FROM SECONDARY SOURCES
2.5.5 PRIMARY SOURCES
2.5.6 KEY DATA POINTS FROM PRIMARY SOURCES
2.5.7 ASSUMPTIONS
3 MARKET ANALYSIS
3.1 INTRODUCTION
3.2 MARKET SEGMENTATION
3.3 FACTORS INFLUENCING MARKET
3.3.1 DRIVERS AND OPPORTUNITIES
3.3.1.1 Rising incidence of cancer
3.3.1.2 increasing preference for blood/urine based liquid biopsy over invasive tissue biopsy procedures
3.3.1.3 rising number of late pregnancies leading to high incidence rate of babies with chromosomal disorders
3.3.1.4 Increasing funding for liquid based test development
3.3.1.5 Technological advancements in liquid biopsy
3.3.1.6 Agreements and collaborations
3.3.1.7 Increasing number of liquid biopsy test launches
3.3.2 RESTRAINTS AND THREATS
3.3.2.1 High cost with less reimbursement facilities
3.3.2.2 Ethical issues related to genetic testing
3.3.2.3 Lack of skilled healthcare professionals
3.3.2.4 Lack of standardization of liquid biopsy tests
3.3.2.5 Regulatory issues
3.4 REGULATORY AFFAIRS
3.4.1 U.S.
3.4.2 EUROPE
3.4.3 CHINA
3.4.4 INDIA
3.4.5 JAPAN
3.5 PORTER’S FIVE FORCE ANALYSIS
3.5.1 THREAT OF NEW ENTRANTS
3.5.2 THREAT OF SUBSTITUTES
3.5.3 COMPETITIVE RIVALRY
3.5.4 BARGAINING POWER OF SUPPLIERS
3.5.5 BARGAINING POWER OF BUYERS
3.6 PATENT TRENDS
3.7 MARKET SHARE ANALYSIS
3.8 REIMBURSEMENT SCENARIO
3.9 CLINICAL TRIALS
3.10 TECHNOLOGICAL ADVANCEMENTS
3.10.1 MICRORNA (MIRNA)
3.10.2 PROTEIN BIOMARKERS
3.10.3 CIRCULATING MRNA
3.10.4 CRISPR PAPER TEST (SHERLOCK)
3.11 UPCOMING TESTS
3.12 RESEARCH USE ONLY CELL-FREE DNA TESTS
3.13 FUNDING SCENARIO
3.14 LIQUID BIOPSY COMPANY COMPARISON BY APPLICATIONS
4 MARKET SIZING
4.1 U.S.LIQUID BIOPSY MARKET SIZING INFORMATION
4.1.1 ONCOLOGY TESTING
4.1.1.1 Early screening
4.1.1.2 Companion diagnostics
4.1.1.3 Prognosis monitoring
4.1.1.4 Recurrence monitoring
4.1.2 NON-INVASIVE PRENATAL SCREENING (NIPT)
4.1.3 TRANSPLANTATION DIAGNOSTICS
5 LIQUID BIOPSY GLOBAL MARKET, BY BIOMARKER
5.1 INTRODUCTION
5.2 CIRCULATING TUMOUR CELLS (CTC)
5.3 CELL-FREE DNA (CFDNA)
5.4 EXOSOMES & OTHERS
6 LIQUID BIOPSY GLOBAL MARKET, BY APPLICATION
6.1 INTRODUCTION
6.2 ONCOLOGY TESTING
6.2.1 CANCER TYPES
6.2.1.1 Introduction
6.2.1.2 Lung cancer
6.2.1.3 Breast cancer
6.2.1.4 Colorectal cancer
6.2.1.5 Melanoma
6.2.1.6 Prostate cancer
6.2.1.7 Ovarian cancer
6.2.1.8 Others
6.2.2 CANCER CARE
6.2.2.1 Introduction
6.2.2.2 Early screening
6.2.2.3 Companion diagnosis
6.2.2.4 Prognosis monitoring
6.2.2.5 Recurrence monitoring
6.3 PRENATAL TESTING
6.4 TRANSPLANTATION
7 LIQUID BIOPSY GLOBAL MARKET, BY SAMPLE
7.1 INTRODUCTION
7.2 BLOOD
7.3 URINE AND OTHERS
8 LIQUID BIOPSY GLOBAL MARKET, BY END-USERS
8.1 INTRODUCTION
8.2 HOSPITALS
8.3 ACADEMIC & RESEARCH INSTITUTES
9 REGIONAL ANALYSIS
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 UNITED STATES
9.2.2 OTHERS
9.3 EUROPE
9.3.1 GERMANY
9.3.2 FRANCE
9.3.3 U.K.
9.3.4 OTHERS
9.4 ASIA-PACIFIC
9.4.1 JAPAN
9.4.2 CHINA
9.4.3 INDIA
9.4.4 OTHERS
9.5 REST OF THE WORLD (ROW)
9.5.1 BRAZIL
9.5.2 REST OF LATIN AMERICA
9.5.3 MIDDLE EAST & OTHERS
10 COMPETITIVE LANDSCAPE
10.1 INTRODUCTION
10.2 AGREEMENTS
10.3 COLLABORATIONS/PARTNERSHIPS
10.4 NEW PRODUCT LAUNCHES
10.5 APPROVALS
10.6 ACQUSTIONS
10.7 OTHERS
11 MAJOR COMPANIES
11.1 BGI (BGI DIAGNOSTICS)
11.1.1 OVERVIEW
11.1.2 FINANCIALS
11.1.3 PRODUCTS NIFTY TEST
11.1.4 KEY DEVELOPMENTS
11.1.5 BUSINESS STRATEGY
11.1.6 SWOT ANALYSIS
11.2 BIOCEPT, INC.
11.2.1 OVERVIEW
11.2.2 FINANCIALS
11.2.3 PRODUCT PORTFOLIO
11.2.4 KEY DEVELOPMENTS
11.2.5 BUSINESS STRATEGY
11.2.6 SWOT ANALYSIS
11.3 CAREDX, INC.
11.3.1 OVERVIEW
11.3.2 FINANCIALS
11.3.3 PRODUCT DESCRIPTION
11.3.4 KEY DEVELOPMENTS
11.3.5 BUSINESS STRATEGY
11.3.6 SWOT ANALYSIS
11.4 CYNVENIO BIOSYSTEMS, INC
11.4.1 OVERVIEW
11.4.2 FINANCIALS
11.4.3 PRODUCT PORTFOLIO
11.4.4 KEY DEVELOPMENTS
11.4.5 BUSINESS STRATEGY
11.4.6 SWOT ANALYSIS
11.5 EUROFINS SCIENTIFIC SE (LIFECODEXX)
11.5.1 OVERVIEW
11.5.2 FINANCIALS
11.5.3 PRODUCT PORTFOLIO
11.5.4 KEY DEVELOPMENTS
11.5.5 BUSINESS STRATEGY
11.5.6 SWOT ANALYSIS
11.6 EXACT SCIENCES CORPORATION
11.6.1 OVERVIEW
11.6.2 FINANCIALS
11.6.3 PRODUCT PORTFOLIO
11.6.4 KEY DEVELOPMENTS
11.6.5 BUSINESS STRATEGY
11.6.6 SWOT ANALYSIS
11.7 EXOSOME DIAGNOSTICS, INC
11.7.1 OVERVIEW
11.7.2 FINANCIALS
11.7.3 PRODUCT PORTFOLIO
11.7.4 KEY DEVELOPMENTS
11.7.5 BUSINESS STRATEGY
11.7.6 SWOT ANALYSIS
11.8 GUARDANT HEALTH, INC.
11.8.1 OVERVIEW
11.8.2 FINANCIALS
11.8.3 PRODUCT DESCRIPTION
11.8.4 KEY DEVELOPMENTS
11.8.5 BUSINESS STRATEGY
11.8.6 SWOT ANALYSIS
11.9 ILLUMINA, INC.
11.9.1 OVERVIEW
11.9.2 FINANCIALS
11.9.3 PRODUCT PORTFOLIO
11.9.4 KEY DEVELOPMENTS
11.9.5 BUSINESS STRATEGY
11.9.6 SWOT ANALYSIS
11.10 IMMUCOR
11.10.1 OVERVIEW
11.10.2 FINANCIALS
11.10.3 PRODUCT PORTFOLIO
11.10.4 KEY DEVELOPMENTS
11.10.5 BUSINESS STRATEGY
11.10.6 SWOT ANALYSIS
11.11 LABORATORY CORPORATION OF AMERICA HOLDINGS
11.11.1 OVERVIEW
11.11.2 FINANCIALS
11.11.3 PRODUCT PORTFOLIO
11.11.4 KEY DEVELOPMENTS
11.11.5 BUSINESS STRATEGY
11.11.6 SWOT ANALYSIS
11.12 MDX HEALTH
11.12.1 OVERVIEW
11.12.2 FINANCIALS
11.12.3 PRODUCT DESCRIPTION
11.12.4 KEY DEVELOPMENTS
11.12.5 BUSINESS STRATEGY
11.12.6 SWOT ANALYSIS
11.13 MYRIAD GENETICS, INC.
11.13.1 OVERVIEW
11.13.2 FINANCIALS
11.13.3 PRODUCT PORTFOLIO
11.13.4 KEY DEVELOPMENTS
11.13.5 BUSINESS STRATEGY
11.13.6 SWOT ANALYSIS
11.14 NATERA, INC.
11.14.1 OVERVIEW
11.14.2 FINANCIALS
11.14.3 PRODUCT PORTFOLIO
11.14.3.1 PANORAMA
11.14.3.2 CONSTELLATION
11.14.3.3 SIGNATERA
11.14.3.4 VISTARA
11.14.4 KEY DEVELOPMENTS
11.14.5 BUSINESS STRATEGY
11.14.6 SWOT ANALYSIS
11.15 ROCHE HOLDINGS AG
11.15.1 OVERVIEW
11.15.2 FINANCIALS
11.15.3 PRODUCT DESCRIPTION
11.15.4 KEY DEVELOPMENTS
11.15.5 BUSINESS STRATEGY
11.15.6 SWOT ANALYSIS
Table 1 LIQUID BIOPSY GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN) 30
Table 2 LIQUID BIOPSY GLOBAL MARKET REVENUE, BY BIOMARKERS (2016-2024) ($MN) 32
Table 3 LIQUID BIOPSY GLOBAL MARKET REVENUE, BY APPLICATIONS, (2016-2024) ($MN) 33
Table 4 LIQUID BIOPSY GLOBAL MARKET REVENUE, BY SAMPLE (2016-2024) ($MN) 34
Table 5 LIQUID BIOPSY GLOBAL MARKET REVENUE, BY END-USERS (2016-2024) ($MN) 35
Table 6 ONCOLOGY TESTING U.S. MARKET 130
Table 7 NIPT GLOBAL TOTAL ADDRESSABLE MARKET (TAM) (HIGH RISK PREGNANCIES) (2017)($MN) 131
Table 8 KIDNEY TRANSPLANTATION DIAGNOSTICS GLOBAL TOTAL ADDRESSABLE MARKET (TAM) (2017)($MN) 132
Table 9 HEART TRANSPLANTATION DIAGNOSTIS GLOBAL TOTAL ADDRESSABLE MARKET (TAM) (2017)($MN) 133
Table 10 LIQUID BIOPSY GLOBAL MARKET REVENUE, BY BIOMARKER (2016-2024) ($MN) 135
Table 11 CIRCULATING TUMOR CELLS GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN) 139
Table 12 CELL-FREE DNA GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN) 143
Table 13 EXOSOMES & OTHERS GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN) 147
Table 14 LIQUID BIOPSY GLOBAL MARKET REVENUE, BY APPLICATIONS (2016-2024) ($MN) 150
Table 15 ONCOLOGY TESTING GLOBAL MARKET REVENUE, BY CANCER TYPE (2016-2024) ($MN) 155
Table 16 ONCOLOGY TESTING GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN) 157
Table 17 LUNG CANCER GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN) 163
Table 18 BREAST CANCER GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN) 168
Table 19 COLORECTAL CANCER GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN) 173
Table 20 MELANOMA GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN) 176
Table 21 PROSTATE CANCER GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN) 180
Table 22 OVARIAN CANCER GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN) 183
Table 23 OTHERS GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN) 188
Table 24 ONCOLOGY TESTING GLOBAL MARKET REVENUE, BY CANCER CARE (2016-2024) ($MN) 191
Table 25 EARLY SCREENING GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN) 193
Table 26 COMPANION DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN) 196
Table 27 PROGNOSIS GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN) 198
Table 28 RECURRENCE MONITORING GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN) 201
Table 29 PRENATAL (NIPT) TESTING GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN) 204
Table 30 TRANSPLANTATION DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN) 207
Table 31 LIQUID BIOPSY GLOBAL MARKET REVENUE, BY SAMPLE (2016-2024) ($MN) 210
Table 32 BLOOD SAMPLE GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN) 213
Table 33 URINE & OTHER SAMPLES GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN) 217
Table 34 LIQUID BIOPSY GLOBAL MARKET REVENUE, BY END-USERS,(2016-2024) ($MN) 220
Table 35 HOSPITALS GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN) 223
Table 36 ACADEMIC & RESEARCH INSTITUTES GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN) 227
Table 37 LIQUID BIOPSY GLOBAL MARKET REVENUE, BY REGION (2016-2024) ($MN) 230
Table 38 NORTH AMERICA LIQUID BIOPSY MARKET REVENUE, BY BIOMARKERS (2016-2024) ($MN) 233
Table 39 NORTH AMERICA LIQUID BIOPSY MARKET REVENUE, BY APPLICATION (2016-2024) ($MN) 235
Table 40 NORTH AMERICA ONCOLOGY TESTING MARKET REVENUE, BY CANCER CARE (2016-2024) ($MN) 236
Table 41 NORTH AMERICA ONCOLOGY TESTING MARKET REVENUE, BY CANCER TYPE (2016-2024) ($MN) 238
Table 42 NORTH AMERCA LIQUID BIOPSY MARKET REVENUE, BY SAMPLE (2016-2024) ($MN) 240
Table 43 NORTH AMERICA LIQUID BIOPSY MARKET REVENUE, BY END-USERS, (2016-2024) ($MN) 242
Table 44 NORTH AMERICA LIQUID BIOPSY MARKET REVENUE, BY COUNTRY, (2016-2024) ($MN) 244
Table 45 EUROPE LIQUID BIOPSY MARKET REVENUE, BY BIOMARKERS (2016-2024) ($MN) 255
Table 46 EUROPE LIQUID BIOPSY MARKET REVENUE, BY APPLICATION (2016-2024) ($MN) 257
Table 47 EUROPE ONCOLOGY TESTING MARKET REVENUE, BY CANCER CARE (2016-2024) ($MN) 258
Table 48 EUROPE ONCOLOGY TESTING MARKET REVENUE, BY CANCER TYPE (2016-2024) ($MN) 260
Table 49 EUROPE LIQUID BIOPSY MARKET REVENUE, BY SAMPLE (2016-2024) ($MN) 262
Table 50 EUROPE LIQUID BIOPSY MARKET REVENUE, BY END-USERS, (2016-2024) ($MN) 264
Table 51 EUROPE LIQUID BIOPSY MARKET REVENUE, BY COUNTRY, (2016-2024) ($MN) 266
Table 52 ASIA-PACIFIC LIQUID BIOPSY MARKET REVENUE, BY BIOMARKERS (2016-2024) ($MN) 285
Table 53 ASIA-PACIFIC LIQUID BIOPSY MARKET REVENUE, BY APPLICATION (2016-2024) ($MN) 287
Table 54 ASIA-PACIFIC ONCOLOGY TESTING MARKET REVENUE, BY CANCER CARE (2016-2024) ($MN) 288
Table 55 ASIA-PACIFIC ONCOLOGY TESTING MARKET REVENUE, BY CANCER TYPE (2016-2024) ($MN) 290
Table 56 ASIA-PACIFIC LIQUID BIOPSY MARKET REVENUE, BY SAMPLE (2016-2024) ($MN) 292
Table 57 ASIA-PACIFIC LIQUID BIOPSY MARKET REVENUE, BY END-USERS, (2016-2024) ($MN) 294
Table 58 ASIA-PACIFIC LIQUID BIOPSY MARKET REVENUE, BY COUNTRY, (2016-2024) ($MN) 296
Table 59 ROW LIQUID BIOPSY MARKET REVENUE, BY BIOMARKERS (2016-2024) ($MN) 315
Table 60 ROW LIQUID BIOPSY MARKET REVENUE, BY APPLICATION (2016-2024) ($MN) 317
Table 61 ROW ONCOLOGY TESTING MARKET REVENUE, BY CANCER CARE (2016-2024) ($MN) 318
Table 62 ROW ONCOLOGY TESTING MARKET REVENUE, BY CANCER TYPE (2016-2024) ($MN) 320
Table 63 ROW LIQUID BIOPSY MARKET REVENUE, BY SAMPLE (2016-2024) ($MN) 322
Table 64 ROW LIQUID BIOPSY MARKET REVENUE, BY END-USERS (2016-2024) ($MN) 324
Table 65 ROW LIQUID BIOPSY MARKET REVENUE, BY COUNTRY, (2016-2024) ($MN) 326
Table 66 AGREEMENTS (2016-2018) 342
Table 67 COLLABORATIONS/PARTNERSHIPS (2016-2018) 355
Table 68 NEW PRODUCT LAUNCH (2016-2018) 363
Table 69 APPROVALS (2016-2018) 370
Table 70 ACQUISITIONS (2016-2018) 373
Table 71 OTHERS (2016-2018) 374
Table 72 BIOCEPT, INC: TOTAL REVENUE AND R&D EXPENSES 2015-2017 ($MN) 388
Table 73 CAREDX, INC.: TOTAL REVENUE AND R&D EXPENSES (2015-2017) ($MN) 401
Table 74 CAREDX, INC.: TOTAL REVENUE, BY SEGMENTS (2015-2017) ($MN) 402
Table 75 CAREDX, INC.: TOTAL REVENUE, BY GEOGRAPHY (2015-2017) ($MN) 403
Table 76 EUROFINS SCIENTIFIC: TOTAL REVENUE AND R&D EXPENSES (2015-2017) ($MN) 416
Table 77 EUROFINS SCIENTIFIC: TOTAL REVENUE, BY GEOGRAPHY (2015-2017) ($MN) 417
Table 78 EXACT SCIENCES CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2015-2017) ($MN) 423
Table 79 ILLUMINA INC: TOTAL REVENUE AND R&D EXPENSES (2015-2017) ($MN) 444
Table 80 ILLUMINA INC: TOTAL REVENUE, BY SEGMENT, (2015-2017) ($MN) 445
Table 81 ILLUMINA INC: TOTAL REVENUE, BY GEOGRAPHY (2015-2017) ($MN) 446
Table 82 IMMUCOR INC.: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN) 451
Table 83 IMMUCOR INC.: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN) 452
Table 84 IMMUCOR INC.: TOTAL REVENUE, BY GEOGRAPHY (2014-2016) ($MN) 453
Table 85 LABCORP.: TOTAL REVENUE AND R&D EXPENSES, (2015-2017) ($MN) 457
Table 86 LABCORP.: TOTAL REVENUE, BY SEGMENT, (2015-2017) ($MN) 458
Table 87 LABCORP.: TOTAL REVENUE, BY GEOGRAPHY, (2015-2017) ($MN) 459
Table 88 MDXHEALTH: TOTAL REVENUE AND R&D EXPENSES, (2015-2017) ($MN) 464
Table 89 MYRAID GENETICS: TOTAL REVENUE AND R&D EXPENSES, (2015-2017) ($MN) 473
Table 90 MYRIAD GENETICS, INC.: TOTAL REVENUE, BY SEGMENTS, (2015-2017) ($MN) 474
Table 91 NATERA, INC.: TOTAL REVENUE AND R&D EXPENSES, (2015-2017) ($MN) 481
Table 92 NATERA, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2015-2017) ($MN) 482
Table 93 ROCHE HOLDINGS AG: TOTAL REVENUE AND R&D EXPENSES, (2015-2017) ($MN) 489
Table 94 ROCHE HOLDINGS AG: TOTAL REVENUE BY SEGMENTS (2015-2017) ($MN) 490
Table 95 ROCHE HOLDINGS AG: DIAGNOSTICS REVENUE BY TYPES (2015-2017) ($MN) 491
Table 96 ROCHE HOLDINGS AG: TOTAL REVENUE, BY GEOGRAPHY, (2015-2017) ($MN) 492
Liquid biopsy is a minimally invasive technology for the detection of molecular biomarkers without the need for invasive procedures. Circulating tumor cells (CTCs), Circulating free DNA (cfDNA), exosomes and others (microvesicles & apoptotic bodies) in the blood can help in diagnosing the disease condition and give clues about which treatments are most likely to work for that patient. The recent interest in nucleic acids present in blood and urine has opened up numerous new areas of investigation and new possibilities for molecular diagnosis. In oncology, tumor-derived genetic changes, epigenetic alterations, and viral nucleic acids have been found in the plasma or serum of cancer patients. These findings have important implications for the detection, monitoring, and prognostication of many types of malignancies. In prenatal diagnosis, the discovery of fetal DNA in maternal plasma and serum has provided a non-invasive source of fetal genetic material for analysis. This development has important implications for the realization of non-invasive prenatal diagnosis and has provided new methods for the monitoring of pregnancy-associated disorders.
Plasma DNA technology has also found recent applications in the fields of organ transplantation, infectious agent detection and monitoring. Future areas of study include circulating RNA in plasma and the elucidation of the biology of release, clearance, and possible functionality of plasma nucleic acids.
According to IQ4I analysis, the liquid biopsy global market was estimated to reach $8,730.4 million by 2024. The factors driving the market are raising incidence of cancer, increasing preference for blood or urine based liquid biopsy, rising number of late pregnancies, technological advancements, increasing funding, agreements and collaborations. Whereas, factor such as high cost of tests with limited reimbursements and regulatory issues are restraining the market growth.
The liquid biopsy market is divided based on biomarkers, applications, sample, end-users and geography. The biomarkers market is further segmented into circulating tumor cells (CTCs), Cell-free DNA and exosomes and other, among them Cell-free DNA commanded the largest share and circulating tumor cells are project to grow at highest CAGR from 2017 to 2024. The applications market is segmented into oncology testing, prenatal non-invasive testing and transplantation diagnostics. The oncology testing commanded the largest revenue of in 2017 and transplantation diagnostics is expected to show highest CAGR growth. The oncology testing market is further segmented based on type of cancer into lung, breast, colorectal, ovarian, prostate, melanoma and others. The breast cancer commanded the largest share in 2017 and lung cancer is expected to grow at double digit CAGR from 2017 to 2024. In segmentation based on cancer care, the application market consists of early screening, companion diagnostics, prognosis and recurrence monitoring. The companion diagnostics commanded the largest revenue in 2017 where as recurrence monitoring is projected to grow at strong double digit CAGR from 2017 to 2024.
The liquid biopsy market by sample source is segmented into blood and urine & others. The blood based tests commanded largest share of the market in 2017 and is project to maintain its leading position from 2017 to 2024. The end-user market consist of Hospitals and academic & research institutes, here hospitals leads the market with revenue in 2017 and also projected to maintain the position till 2024.
Geographically, the market is segmented into North America, Europe, Asia-Pacific and RoW. The North America dominates the market with share in 2017 due to rising aging population, late pregnancies, preference for non-invasive tests where as Asia-Pacific is projected to be fastest growing market with high CAGR from 2017 to 2024 due to increasing affluence, awareness and increasing incidence of cancer in the region.
Technological advancements in liquid biopsy are expansion of applications beyond cancer diagnostics and monitoring to include other conditions such as cardiac health and infectious diseases and exploring of new sources for liquid biopsy such as miRNA, protein biomarkers and circulating MRNA. A paper based dip test called has been developed by scientists from Broad institute of MIT and Harvard, SHERLOCK, that make use of Cas13 CRISPR associated protein that bind to specific RNA to identify specific targets. This test is expected to detect tumor DNA in the near future.
The possibility of detection of health condition of an individual based on simple blood test has ignited imagination of scientific community and a flurry of activity has been unleashed. The absence of rigorous regulatory requirement as in case of a drug or a medical device also reduces the time to market for these tests which is attracting private investments. Some of the recent investments are funding of $40 million to MedGenome Labs Ltd by group of investors (HDFC, Sequoia, Sofina s.a. Zodiac Capital for expansion of clinical genomic testing of NIPT, Series C funding of DiaCarta in February 2018, to Support Company’s core XNA technology and expansion of diagnostic products. Biggest of them all investment of $900 million in GRAIL, Inc a spinoff of Illumina by Johnson & Johnson and Jeff Bezos of Amazon for development of ctDNA based tests.
The liquid biopsy market is consolidated and is dominated by players such Myriad Genetics (U.S.), Exact Sciences (U.S.), LabCorp (U.S.), Natera (U.S.), Roche Diagnostics (Switzerland) to name a few. Companies in this market are employing both organic strategies such as new product launches, approvals collaborations and partnerships while inorganic strategies like acquisition to gain market share. For instance, Launch of Panorama NIPT from Natera for screening of twin pregnancies, approval for BGI to offer NIFTY test in Thailand. Inorganic strategy such as acquisition expands product offering or help in gaining access to new markets. For instance, acquisition of share of GATC Biotech in LifeCodexx by Eurofins or acquisition of Sequenom by Laboratory Corporation has facilitated these companies to expand their product offering.
BGI (China), Biocept (U.S.), CareDx (U.S.), Cynvenio (U.S.), Eurofins (LifeCodexx) (Luxembourg), Exact Sciences (U.S.), Exosome Diagnostics (U.S.), Guardant Health (U.S.), LabCorp. (U.S.), MDx Health (U.S.), Natera (U.S.) Myriad Genetics (U.S.), Laboratory Corporation of America Holding (Sequenom) (U.S.), Roche (Switzerland), Immucor (U.S.), Cynvenio (U.S.) are major companies offering liquid biopsy tests.
